
Bayer, GermanyThe group announced on Thursday that it would buy US biopharmaceutical company Vividion Therapeutics for up to $2 billion to strengthen its ability to discover new treatments and increase the value of its drug pipeline.
The deal is expected to close in the third quarter. Bayer will pay $1.5 billion first and up to $500m when Vividion's business reaches certain milestones in the future.